Atlas closes eleventh fund with $350M

Atlas Venture said it closed its eleventh fund, Atlas Fund XI, at an oversubscribed $350 million. The firm invests in drug discovery platforms and asset-centric product plays, and focuses predominantly on early stage investments and company creation.

In 2015, Atlas closed its $280 million Fund X, its first fund as a life sciences-only firm (see BioCentury, April 20, 2015)...